Drug Discovery Industry Roundup with Barry Bunin — July, 22 2024
Collaborative Drug
JULY 22, 2024
Is Revolutionizing Drug Development. Holy Grail for Weight-Loss Drugs Is Sleep Apnea? DNA Discovery that Could Help Find Pancreatic Cancer Cure.
Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development
Alta Sciences
FEBRUARY 19, 2025
Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Data-Driven Future of Drug Development
DrugBank
OCTOBER 17, 2024
Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.
Navigating the challenges and opportunities of AI in drug development and personalised medicine
Drug Target Review
JULY 18, 2023
Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. This means that we are not doing something right.
DNA Analysis Finds New Target for Diabetes Drugs
NIH Director's Blog: Drug Development
MARCH 11, 2014
Credit: Jane Ades, National Human Genome Research Institute, NIH Type 2 diabetes (T2D) tends to run in families, and over the last five years the application of genomic technologies has led to discovery of more than 60 specific DNA variants that contribute to risk.
DNA 
52
52 
#ScienceSaturday: January 13, 2024
KIF1A
JANUARY 13, 2024
As one cell turns into two, its DNA must be replicated and then pulled apart, so that when the cell divides each has all the DNA it needs to function. The strands that pull the DNA apart are composed of microtubules, and kinesins like KIF1A and KIF13B can impact the direction the strands pull in.
DNA 105
105 
FDA Approves Duvystat, New Oral Treatment for Duchenne Muscular Dystrophy (DMD)
PLOS: DNA Science
MARCH 28, 2024
It “could have been easily repurposed for DMD,” said Pier Lorenzo Puri at Sanford Burnham Prebys Medical Discovery Institute in San Diego, who has been working on the drug development since 2004. MDA supported development of a mouse model that enabled the preclinical studies of what would become Duvyzat.
FDA Approval 96
96 
Five Promising Treatment Areas in Early-Phase Drug Development in 2024
Alta Sciences
APRIL 17, 2024
Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
Arylidene and amino spacer?linked rhodanine?quinoline hybrids as upgraded antimicrobial agents
Chemical Biology and Drug Design
SEPTEMBER 12, 2023
In the drug development process, linker hybrids acquire the top position due to their excellent π-stacking and Van der Waals interaction with the DNA active sites of pathogens. This review highlights the recent advances (2013–2023) in the pharmacology of rhodanine-linked quinoline hybrids as more effective antimicrobial agents.
DNA 100
100 
From Impossible to Inevitable: Transforming Undruggable Targets
DrugBank
MAY 22, 2024
Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins. DNA and RNA are also key players, each bringing unique challenges. Many cancer treatments target DNA, but often these can cause collateral damage, leading to severe side effects.
Unlocking the Future of Personalized Medicine: Blood vs. Buccal Swab in Pharmacogenomics Testing
Conversations in Drug Development Trends
JUNE 13, 2024
At Worldwide, our recent study delved into the intricacies of PGx, comparing two common methods of DNA sample collection: buccal swabs and blood samples. These results are largely due to the higher cell density in blood, which includes DNA-rich white blood cells. for buccal swabs and 93.2% for blood samples.
DNA 72
72 
New understanding of the TMEJ pathway in cancer
Drug Target Review
DECEMBER 14, 2023
Throughout the course of our lives, natural and environmental factors can break DNA. Breaks in both DNA strands are a particularly dangerous threat to genome stability. At a DNA double-strand break (DSB), potentially lost sequence information cannot be recovered from the same DNA molecule.
DNA 59
59 
The science of ageing and restoring healthspan
Drug Target Review
JANUARY 8, 2024
We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. The epigenome drifts with age, leading to dysregulated gene expression.
Science 145
145 
Medicinal Chemistry In The Age Of Artificial Intelligence
LifeSciVC
AUGUST 5, 2024
We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more.
Logistics in Focus: Orchestrating the Challenges of Cell Therapy
Conversations in Drug Development Trends
NOVEMBER 12, 2024
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition.
Therapies 72
72 
Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs
Alta Sciences
APRIL 16, 2024
Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs pmjackson Tue, 04/16/2024 - 19:04 The gene therapy landscape continues to accelerate in preclinical and clinical research, with programs constantly in development for targeted, personalized medicines. But how are PCR analysis techniques applied?
Therapies 52
52 
Unlocking Undruggable Targets: Shifting Paradigms in Modern Drug Discovery
DrugBank
MAY 15, 2024
Its structure makes it incredibly difficult for drugs to bind effectively, which has stymied drug development for decades. The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding.
Missing Genes Point to Possible Drug Targets
NIH Director's Blog: Drug Development
APRIL 18, 2017
Every person’s genetic blueprint, or genome, is unique because of variations that occasionally occur in our DNA sequences. As promising as it may be, this collection of 1,300 or so human gene knockouts in Pakistan represents what is likely just the start of a rapidly growing area of scientific research and drug development.
Drugs 52
52 
UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials | 2020-12-21
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
The Pharma Data
SEPTEMBER 11, 2021
We have the ability to generate precise antibodies to a diverse range of targets, which together with Boehringer Ingelheim’s strength in drug development capabilities, could mean multiple new, more personalized treatments in the future for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. About Twist Biopharma.
DNA 52
52 
Rapid delivery of toxicological material
Drug Target Review
SEPTEMBER 10, 2024
The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. Hence, in many cases an earlier IND may be prevented by the timely provision of representative Drug Substance (DS) to execute such toxicology studies.
The power of combinations in blood cancers
Drug Target Review
NOVEMBER 6, 2023
To be successful, surrogate or intermediate endpoints will need to be established to accelerate the development of the new regimens. At AstraZeneca and beyond we are exploring the use of cell-free DNA (cfDNA) methods to assess minimal residual disease as a possible intermediate endpoint across several disease types.
Small Molecule 111
111 
How to find a drug: the past, present and future of small molecule drug discovery?
DrugBaron
JULY 19, 2022
The first is the growing popularity of DNA-encoded libraries (DELs). Here, libraries are constructed on DNA tags in a variety of different ways, but in essence in a broadly similar way to the creation of a virtual chemical space. Two solutions, one physical and one computational have emerged.
Small Molecule 100
100 
#Unshackled: The evolving definition of asset-centricity
DrugBaron
OCTOBER 17, 2022
Buoyed by the string of successes in early discovery delivered by this approach, attention inevitably turned to how we might leverage the same insights to improve return on capital in the rest of the long path through drug development. But how to proceed? Will it work?
Pharma Companies 100
100 
Mutations in Three Genes Protect Against Alzheimer’s
PLOS: DNA Science
APRIL 18, 2024
That’s why we are excited about the discovery of this variant in fibronectin, which may be a good target for drug development,” said study co-leader Richard Mayeux. ” The post Mutations in Three Genes Protect Against Alzheimer’s appeared first on DNA Science.
Disease 95
95 
The Future of Drug Discovery: Tackling the Undruggable with New Biotechnologies
DrugBank
JULY 24, 2024
This was the first successful drug development against a transcription factor, opening the door to targeting a whole new class of previously unreachable targets. The Promise of Multispecific Drugs The future of drug discovery looks even brighter with the development of multispecific drugs.
The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans
Conversations in Drug Development Trends
AUGUST 14, 2024
A few notable developments include: Liquid Biopsy Technologies Liquid biopsy technologies involve analyzing biomarkers from bodily fluids to detect and monitor cancers, offering a non-invasive alternative to traditional biopsies. However, at Worldwide, we have a proven track record of successfully utilizing biomarkers in oncology development.
Treatment 78
78 
Evaluating Impurities in New Drugs to Prevent Delays in Development
The Premier Consulting Blog
JULY 9, 2023
Assessment and control of DNA reactive impurities Another important guidance document related to impurities and degradants in new small molecule drugs is ICH M7(R1). What sets this guidance apart from ICH Q3A and ICH Q3B is that it applies to all stages of clinical development, not just to approval. link] ICH M7 (R2)- Q&A.
Missing Metabolites
Metabolite Tales Blog
OCTOBER 5, 2023
Missing metabolites Accounting for metabolites is a key activity in drug development programs. Sometimes biotransformations result in metabolites that might not be spotted initially.
Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers
The Pharma Data
DECEMBER 14, 2020
. The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). Our mission is to transform and accelerate the cancer drug development process.
New insights into the role of viral capsids in gene therapy safety
Drug Target Review
DECEMBER 5, 2024
2 Structure and function of AAV capsids in gene therapy Wild-type AAV is composed of a protein shell (capsid) that contains a single-stranded DNA genome encoding proteins involved in viral replication, structure and assembly. Therefore, vectors based on these serotypes may enable targeted gene delivery and optimal transduction efficiency.
Therapies 52
52 
Next Generation Sequencing (NGS) in Clinical Trials: Challenges and Opportunities
Vial
DECEMBER 5, 2023
It has become a fundamental tool for researchers to explore the complexities of genetic information and conduct genetic-informed drug development. Sponsors have used NGS to screen patients for clinical trial eligibility and patient stratification , expanded CDx development, and comprehensive genomic profiling (CGP).
Bringing science and medicine together to help patients with cancer
The Pharma Data
SEPTEMBER 14, 2020
Clinical trial investigators are the eyes and ears in the clinic for pharmaceutical drug developers. They are seeing the patients and have the best understanding of how patients are tolerating a new drug and how compelling the anti-cancer effects are. To do this, we need to innovate in the clinical trial space.
Science 52
52 
Puerto Rico CIO & IT Leadership Conference Recap
Perficient: Drug Development
OCTOBER 20, 2023
Private and public organizations recognize that the need to innovate is a constant necessity, and they are looking for partners with innovation in their DNA to help them navigate these dynamic and constant changes. We bring global expertise and local know-how that enables transformation and spurs business velocity and growth.
DNA 64
64 #WhyIScience Q&A: A biochemist uses mass spectrometry to find proteins involved in cancer
Broad Institute
JUNE 11, 2024
After graduating from college, Haines moved closer to his passion for proteomics, working as an analytical development research scientist for a pharmaceutical company in Albany, NY before relocating to Massachusetts. As the startup struggled to find funding, Haines heard about the Proteomics Platform at the Broad Institute of MIT and Harvard.
Science 81
81 
How nucleolar stress accelerates aging in mice
Drug Target Review
APRIL 9, 2024
For his postdoctoral stay he joined the group of André Nussenzweig, where he started to work on DNA repair, particularly focusing on the role of histone H2AX. In 2005, he joined CNIO to lead the Genomic Instability Group where he has been ever since.
RNA 65
65 
Winship Cancer Institute of Emory University Joins Caris’ Precision Oncology Alliance
The Pharma Data
OCTOBER 19, 2020
The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.
Patient Safety and Radiopharmaceuticals Administration: Minimizing Radiation Exposure and Risks
Conversations in Drug Development Trends
JULY 8, 2024
Genetic Factors : Certain genetic mutations, such as those in DNA repair genes, can affect how cells respond to radiation. Individuals with familial cancer syndrome may have inherited mutations that predispose them to cancer development, affecting genes involved in DNA repair and cell cycle regulation.
Exploring the Future of Oncology with ADCs and TILs: Key Insights From ASCO
Conversations in Drug Development Trends
JUNE 21, 2024
Although there are a range of efficacies across different tumor types that require a greater understanding, the use of circulating tumor DNA profiles holds promise for personalized treatment strategies that better target the drug for the patient, potentially revolutionizing how ADCs are deployed in clinical practice.
The evolution of cell therapy to address unmet medical needs
Drug Target Review
JUNE 19, 2024
The other powerful benefit is that our cell lines can become any of the cell types of the human body – these cells have within their DNA the capability to become any of the more than 200 human cell types which you might want to manufacture. This provides some regulatory advantages, and of course, significant cost advantages.
Therapies 84
84 
Overcoming operational challenges in CGT manufacturing with AI
Drug Target Review
SEPTEMBER 18, 2024
Companies are planning their drug development strategies with automated unit operations in mind, and how to incorporate them earlier in the development pipeline. Throughout his career in the industry, Dalip has been engaged in developing technologies and methods for use in cell therapy applications.
Therapies 52
52 
Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer
The Pharma Data
JUNE 28, 2021
Bayer’s acquisition of Noria and PSMA Therapeutics, which have nurtured Dr. Babich’s radiopharmaceutical and diagnostic technology, is an important milestone in drug development, and we look forward to the advances this collaboration can make to enhance prostate cancer therapies.”.
Precision Medicine in the Genomic Era
DrugBank
JUNE 27, 2023
The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.
Disease 98
98 
Unity Catalog, the Well-Architected Lakehouse and Performance Efficiency
Perficient: Drug Development
AUGUST 31, 2024
This is why monitoring needs to be built onto your development DNA. Monitor Performance Databricks has different built-in monitoring capabilities for different types of jobs and workflows. Monitor entire SQL Warehouses. Get more granular with the query profiler to identify bottlenecks in different query tasks.
Government 52
52 
Let's personalize your content